Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C [clinicaltrials:NCT00122616]

Bio2RDF uri

Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C [clinicaltrials:NCT00122616]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00122616

Bio2RDF identifier

NCT00122616

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00122616

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The aim of this study i ...... y and a second 2 years after.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy of Pegylated Interfer ...... tient With HIV and Hepatitis C

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:9f544d4897471227dcb417ee7217fda1]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:39063ef3c4f16bf9391501387e9ede29]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:39c7c1eef3c91eeac4d584a5a44ae6d9]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:3d56f62468b86a4fdb019353188e8028]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:4921a4beb219d512b8e6550927bc446d]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:4d1d234496d8f1b40155eed350a95654]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:684af9e7b3663d450ebbf08758bf7083]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:a22faf245126d0268154edda67f68681]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:b417181fea4ebc3fedfe355fe095ad5a]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:b496c785d3e81f6299e5b87fd771e5f3]

collaborator [clinicaltrials_vocabulary:collaborator]

French National Agency for Research on AIDS and Viral Hepatitis [clinicaltrials_resource:70aef9de6f48dc8b934933b4434a772f]

completion date [clinicaltrials_vocabulary:completion-date]

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Hepatitis C, Chronic [clinicaltrials_resource:0fd1a99a08ed2ea914d6bad9cf276bd0]

HIV Infections [clinicaltrials_resource:3f980d9baec1b9b18d5a0f38f4921607]

condition browse [clinicaltrials_vocabulary:condition-browse]

Hepatitis A [clinicaltrials_resource:0386900adf8d2bb222adeaf03c043051]

Hepatitis C, Chronic [clinicaltrials_resource:0fd1a99a08ed2ea914d6bad9cf276bd0]

HIV Infections [clinicaltrials_resource:3f980d9baec1b9b18d5a0f38f4921607]

Hepatitis [clinicaltrials_resource:5a1804a695578df7b58e6501deaaa093]

Hepatitis C [clinicaltrials_resource:75720a68fcdffe391a3e772955910bcb]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Hepatitis A [clinicaltrials_resource:0386900adf8d2bb222adeaf03c043051]

Hepatitis C, Chronic [clinicaltrials_resource:0fd1a99a08ed2ea914d6bad9cf276bd0]

HIV Infections [clinicaltrials_resource:3f980d9baec1b9b18d5a0f38f4921607]

Hepatitis [clinicaltrials_resource:5a1804a695578df7b58e6501deaaa093]

Hepatitis C [clinicaltrials_resource:75720a68fcdffe391a3e772955910bcb]

country [clinicaltrials_vocabulary:country]

France [clinicaltrials_resource:0309a6c666a7a803fdb9db95de71cf01]

detailed description [clinicaltrials_vocabulary:detailed-description]

C hepatitis in HIV infe ...... of the study is 96 weeks

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00122616 [clinicaltrials_resource:a1d82c78741db97ce9fbd87012459da1]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

HIV antiretroviral therapy [clinicaltrials_resource:4c1ed47a19f0d89ef5704e63766e89b8]

HIV antiretroviral therapy [clinicaltrials_resource:cb6aed32454f917dee2f4ce5615b4774]

Ribavirin [clinicaltrials_resource:dd311a84beffef53994f14b4b2c08a52]

Peginterferon alpha-2a (Pegasys®) [clinicaltrials_resource:df37b350b525108cea69af4e7bcf2353]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Interferon-alpha [clinicaltrials_resource:411321421382b10c54a06fd59fb19d27]

Interferons [clinicaltrials_resource:ac14a704eab186e8681cb6c21160bdb2]

Ribavirin [clinicaltrials_resource:c260972ef8fb801d491757e72eeceb79]

Peginterferon alfa-2a [clinicaltrials_resource:ea2504b16a94f43e40b345f0551d81c0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

HIV infections

http://www.w3.org/2001/XMLSchema#string

Hepatitis C, Chronic

http://www.w3.org/2001/XMLSchema#string

Treatment Experienced

http://www.w3.org/2001/XMLSchema#string

Treatment Failure

http://www.w3.org/2001/XMLSchema#string

peginterferon alfa-2a

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

French National Agency for Research on AIDS and Viral Hepatitis [clinicaltrials_resource:70aef9de6f48dc8b934933b4434a772f]

location [clinicaltrials_vocabulary:location]

Service de Maladies Infectieuses et de Réanimation Médicale [clinicaltrials_resource:2f24afc673ef14c481d5d9634f0f7806]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00122616

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Efficacy of Pegylated Interfer ...... nt for HCV. ANRSHC12 Fibrostop

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

ANRSHC12 FIBROSTOP

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Jean Marc Chapplain, MD [clinicaltrials_resource:9594cf89cca19cff8452672a5e03465a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) [clinicaltrials_resource:eef6ed2b2b3b894d68f2c2791d82cfb5]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

French National Agency for Research on AIDS and Viral Hepatitis [clinicaltrials_resource:70aef9de6f48dc8b934933b4434a772f]

start date [clinicaltrials_vocabulary:start-date]

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00122616 study design [clinicaltrials_resource:6e97bd165173cd7862ed8e71286d4db8]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00122616

verification date [clinicaltrials_vocabulary:verification-date]

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00122616

http://www.w3.org/2001/XMLSchema#string

title

Efficacy of Pegylated Interfer ...... tient With HIV and Hepatitis C

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy of Pegylated Interfer ...... C [clinicaltrials:NCT00122616]

@en